Advocacy intelligence hub — real-time data for patient organizations
Celldex Therapeutics — PHASE3
Granular Therapeutics Limited — PHASE1
Blueprint Medicines Corporation — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
ILARIS
(canakinumab)Orphan drugstandardNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutr...
Arcalyst
(rilonacept)Orphan drugstandardKiniksa Pharmaceuticals, Ltd.
12.1 Mechanism of Action Rilonacept is an interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling b...
Robert Evans, PharmD.
Regeneron Pharmaceuticals
Hirsh D Komarow, M.D., M.D
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Chan Yong Jun
Gachon University Gil Oriental Medicine Hospital
📍 NEW YORK, NY
Laura A. Finlayson MD FRCPC
Nova Scotia Health Authority
Simon Haroutounian, PhD
Washington University School of Medicine
JIN-MOO LEE, Ph. D
Kyung Hee University Hospital at Gangdong